Date: 2013-04-12
Type of information: Fundraising
Company: Neuronax (France)
Investors: WiSEED investors community
Amount: 150 k€
Funding type: crowdfunding
Planned used: The funds will be used to support phase 1-2 clinical development of Neuronax lead product, NX210 and to launch preclinical research on NS640.
Others: Neuronax, a french company developing candidate drugs for neural repair, has used crowfunding to raise money to fund the clinical development of its lead project NX210. NX210, a peptide derived from a protein naturally secreted by specialized ependymal cells in the central nervous system, has shown neuroprotective and neurorestorative properties. It could be used to promote regeneration of nerve fibers and to treat traumatic injuries of the central nervous system. Preclinical regulatory studies have been performed and Neuronax expects to initiate a phase 1-2 clinical trial this year.
Therapeutic area: CNS diseases
